Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

Core Insights - Addex Therapeutics reported its financial results for Q3 and YTD 2025, highlighting a focus on developing novel small molecule allosteric modulators for neurological disorders [1][4] Financial Performance - Income for Q3 2025 was CHF 50,000, a decrease of CHF 8,000 from Q3 2024, and year-to-date income was CHF 157,000, down CHF 251,000 compared to the same period in 2024 [3] - R&D expenses increased to CHF 228,000 in Q3 2025 from CHF 204,000 in Q3 2024, while year-to-date R&D expenses decreased to CHF 619,000 from CHF 789,000 [3][5] - G&A expenses for Q3 2025 were CHF 518,000, up from CHF 476,000 in Q3 2024, with year-to-date G&A expenses decreasing to CHF 1,573,000 from CHF 1,929,000 [3][6] - The total operating loss for Q3 2025 was CHF 696,000, compared to CHF 622,000 in Q3 2024, with a year-to-date total operating loss of CHF 2,035,000, an improvement from CHF 2,310,000 [3] - Net loss from continuing operations for Q3 2025 was CHF 1,577,000, slightly higher than CHF 1,528,000 in Q3 2024, while year-to-date net loss increased to CHF 5,009,000 from CHF 3,720,000 [3][8] - Basic and diluted net loss per share for the nine-month period was CHF 0.05, compared to a profit of CHF 0.08 in the same period of 2024 [9] Cash Position - Cash and cash equivalents decreased to CHF 2.2 million as of September 30, 2025, from CHF 3.3 million a year earlier, primarily due to operating activities [10] Corporate Developments - The company is advancing its GABAB positive allosteric modulator candidate for chronic cough and dipraglurant for post-stroke recovery [2][14] - Addex holds a 20% equity interest in Neurosterix US Holdings LLC, which is developing a portfolio of allosteric modulator programs [14]